NIB Holdings Ltd (ASX: NHF) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
NIB Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
NIB Holdings Ltd (ASX: NHF)
Latest News
Healthcare Shares
Is this beaten-down ASX healthcare share a bargain buy now?
Broker Notes
Don't miss these changes to broker ratings on ASX shares
Financial Shares
Why did the NIB share price just hit a 3-year low?
Healthcare Shares
Down 20%, is the NIB share price undervalued?
Financial Shares
Down 21% this year, are NIB shares a buy?
Dividend Investing
How I'd build an ASX passive income portfolio with $10k
Healthcare Shares
Here's why ASX 200 health insurance shares like Medibank are being trounced today
Cheap Shares
History says these 3 ASX shares are dirt cheap today
Best Shares
Top ASX shares to buy in October 2024
Dividend Investing
Why Goldman Sachs rates these ASX 200 dividend stocks as buys
Share Market News
7 ASX 200 directors sell huge chunks of company shares
Healthcare Shares
NIB shares slip as health insurer responds to ASX, investors
Frequently Asked Questions
-
The company was established as Newcastle Industrial Benefits (NIB) Hospital Fund in 1952 to provide health insurance for workers at BHP Steelworks, Mayfield. It changed its name to NIB Health Funds Ltd in 1966.
In 2007 members voted in favour of demutualising the health fund, and in November that year, NIB became the first Australian private health insurer to list on the ASX.
-
NIB pays a fully franked dividend in April and October.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
05 Sep 2024 | $0.1400 | 100.00% | Final | 08 Oct 2024 |
07 Mar 2024 | $0.1500 | 100.00% | Interim | 10 Apr 2024 |
04 Sep 2023 | $0.1500 | 100.00% | Final | 03 Oct 2023 |
02 Mar 2023 | $0.1300 | 100.00% | Interim | 03 Apr 2023 |
05 Sep 2022 | $0.1100 | 100.00% | Final | 04 Oct 2022 |
03 Mar 2022 | $0.1100 | 100.00% | Interim | 04 Apr 2022 |
02 Sep 2021 | $0.1400 | 100.00% | Final | 05 Oct 2021 |
04 Mar 2021 | $0.1000 | 100.00% | Interim | 06 Apr 2021 |
03 Sep 2020 | $0.0400 | 100.00% | Final | 06 Oct 2020 |
05 Mar 2020 | $0.1000 | 100.00% | Interim | 07 Apr 2020 |
02 Sep 2019 | $0.1300 | 100.00% | Final | 30 Sep 2019 |
06 Sep 2018 | $0.1100 | 100.00% | Final | 05 Oct 2018 |
01 Mar 2018 | $0.0900 | 100.00% | Interim | 03 Apr 2018 |
07 Sep 2017 | $0.0000 | 100.00% | Final | 06 Oct 2017 |
02 Mar 2017 | $0.0850 | 100.00% | Interim | 03 Apr 2017 |
08 Sep 2016 | $0.0900 | 100.00% | Final | 07 Oct 2016 |
02 Mar 2016 | $0.0575 | 100.00% | Interim | 01 Apr 2016 |
10 Sep 2014 | $0.0900 | 100.00% | Special Cash | 03 Oct 2014 |
10 Sep 2014 | $0.0575 | 100.00% | Final | 03 Oct 2014 |
05 Sep 2013 | $0.0500 | 100.00% | Final | 04 Oct 2013 |
04 Mar 2013 | $0.0500 | 100.00% | Interim | 05 Apr 2013 |
05 Mar 2012 | $0.0425 | 100.00% | Interim | 05 Apr 2012 |
07 Mar 2011 | $0.0400 | 100.00% | Interim | 08 Apr 2011 |
05 Mar 2010 | $0.0200 | 100.00% | Interim | 08 Apr 2010 |
14 Sep 2009 | $0.0440 | 100.00% | Final | 09 Oct 2009 |
NHF ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About NIB Holdings Ltd
NIB Holdings Limited (ASX: NHF) provides health and medical insurance to more than 1.5 million Australian and New Zealand residents.
In addition, it covers more than 180,000 international students and workers in Australia.
The company also offers travel insurance through its NIB Travel business, and provides health insurance plans to corporate groups through its GU Health business.
NHF Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
22 Nov 2024 | $5.60 | $0.03 | 0.54% | 912,014 | $5.62 | $5.66 | $5.56 |
21 Nov 2024 | $5.57 | $-0.07 | -1.24% | 1,040,138 | $5.70 | $5.75 | $5.54 |
20 Nov 2024 | $5.64 | $-0.11 | -1.91% | 664,185 | $5.73 | $5.75 | $5.64 |
19 Nov 2024 | $5.75 | $0.02 | 0.35% | 555,437 | $5.72 | $5.81 | $5.70 |
18 Nov 2024 | $5.73 | $-0.06 | -1.04% | 794,690 | $5.75 | $5.78 | $5.70 |
15 Nov 2024 | $5.79 | $0.08 | 1.40% | 810,713 | $5.78 | $5.81 | $5.74 |
14 Nov 2024 | $5.71 | $0.01 | 0.18% | 1,045,229 | $5.70 | $5.76 | $5.69 |
13 Nov 2024 | $5.70 | $-0.26 | -4.36% | 1,639,921 | $5.64 | $5.80 | $5.61 |
12 Nov 2024 | $5.96 | $-0.04 | -0.67% | 2,397,746 | $5.70 | $6.04 | $5.58 |
11 Nov 2024 | $6.00 | $-0.08 | -1.32% | 658,341 | $6.10 | $6.14 | $5.99 |
08 Nov 2024 | $6.08 | $0.05 | 0.83% | 606,436 | $6.08 | $6.14 | $6.07 |
07 Nov 2024 | $6.03 | $0.11 | 1.86% | 1,221,464 | $6.03 | $6.09 | $5.98 |
06 Nov 2024 | $5.92 | $0.11 | 1.89% | 575,617 | $5.87 | $5.95 | $5.84 |
05 Nov 2024 | $5.81 | $-0.02 | -0.34% | 741,190 | $5.78 | $5.83 | $5.77 |
04 Nov 2024 | $5.83 | $0.02 | 0.34% | 855,508 | $5.87 | $5.87 | $5.80 |
01 Nov 2024 | $5.81 | $0.03 | 0.52% | 864,072 | $5.76 | $5.84 | $5.72 |
31 Oct 2024 | $5.78 | $-0.04 | -0.69% | 1,730,091 | $5.82 | $5.86 | $5.76 |
30 Oct 2024 | $5.82 | $-0.06 | -1.02% | 1,009,458 | $5.87 | $5.89 | $5.82 |
29 Oct 2024 | $5.88 | $-0.03 | -0.51% | 920,034 | $5.91 | $5.95 | $5.85 |
28 Oct 2024 | $5.91 | $-0.05 | -0.84% | 924,201 | $5.96 | $5.96 | $5.89 |
25 Oct 2024 | $5.96 | $0.02 | 0.34% | 676,858 | $5.94 | $6.02 | $5.93 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
18 Nov 2024 | Mark Fitzgibbon | Sell | 35,000 | $201,202 |
On-market trade.
|
15 Nov 2024 | Mark Fitzgibbon | Sell | 35,000 | $203,000 |
On-market trade.
|
12 Sep 2024 | Mark Fitzgibbon | Sell | 81,760 | $477,719 |
On-market trade.
|
11 Sep 2024 | Mark Fitzgibbon | Sell | 58,240 | $334,921 |
On-market trade.
|
10 Sep 2024 | Mark Fitzgibbon | Sell | 60,000 | $346,435 |
On-market trade.
|
02 Sep 2024 | Mark Fitzgibbon | Buy | 85,685 | $550,097 |
On-market trade.
|
02 Sep 2024 | Mark Fitzgibbon | Expiry | 12,813 | $82,259 |
As advised by the company. Lapsed, 907,024 Rights
|
02 Sep 2024 | Mark Fitzgibbon | Issued | 301,979 | $1,938,705 |
Conversion of securities.
|
02 Sep 2024 | Mark Fitzgibbon | Exercise | 301,979 | $1,938,705 |
Conversion of securities. 605,045 Rights
|
27 Aug 2024 | Jill Watts | Buy | 4,885 | $29,945 |
On-market trade.
|
27 Aug 2024 | Brad Welsh | Buy | 3,174 | $19,044 |
On-market trade.
|
18 Apr 2024 | Mark Fitzgibbon | Transfer | 20,000 | $152,000 |
Off-market transfer.
|
18 Apr 2024 | Mark Fitzgibbon | Transfer | 20,000 | $152,000 |
Off-market transfer.
|
12 Mar 2024 | Mark Fitzgibbon | Sell | 35,000 | $277,018 |
On-market trade.
|
08 Dec 2023 | Jill Watts | Buy | 3,154 | $23,497 |
On-market trade.
|
01 Dec 2023 | Mark Fitzgibbon | Issued | 195,046 | $1,503,804 |
Issue of securities. 9,19,837 Rights
|
23 Nov 2023 | Mark Fitzgibbon | Transfer | 22,000 | $165,000 |
Off-market transfer.
|
23 Nov 2023 | Mark Fitzgibbon | Transfer | 22,000 | $165,000 |
Off-market transfer.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr David L Gordon | Non-Executive DirectorNon-Executive Chairman | May 2020 |
Mr Gordon has over 30 years of of experience as a director of public and private companies and in corporate advisory roles to Australian and international organisations. He brings knowledge of strategy development, mergers and acquisitions, as well as capital raisings, IPOs and joint ventures. David also has a track record in guiding businesses to grow and harness their digital capability to explore and develop new products and markets. David has held a number of roles with Freehills (Partner) and boutique investment bank Wentworth Associates. In addition, he founded independent corporate advisory and investment firm, Lexicon Partners in 2001. David is currently Chair of Accent Group Limited. He is Chair of General Homecare Holdings Pty Ltd, Shippit Pty Ltd, Genesis Capital Manager I Pty Ltd and Genesis Capital Manager II Pty Ltd (the management entities of the Genesis Capital Fund I and Genesis Capital Fund II healthcare investment funds, respectively). He is also a Non-Executive Director of international not-for-profit organisation, High Resolves.
|
Ms Anne Joan Loveridge | Non-Executive Director | Feb 2017 |
Ms Loveridge has over 35 years of experience in the regulated financial services sector, including health insurance. She has knowledge of financial and regulatory reporting, risk management and compliance frameworks. She also has over eight years of experience as a Non-Executive Director for ASX-listed entities in the financial services sector. Formally trained as a Chartered Accountant, Anne has experience in financial reporting, auditing, risk, ethics and regulatory affairs following her 31 years with PwC in the UK and Australia, where she was a Senior Audit Partner and Deputy Chair of the Australian Firm until 2015. Anne is a Non-Executive Director of National Australia Bank Limited, Platinum Asset Management and Accent Group Limited. Anne is a Non-Executive Director of Destination NSW. Anne was appointed to the Board of nib holdings limited in February 2017. She is the Chair of the Audit Committee and a member of the Nomination Committee and the Risk and Reputation Committee. She is member of Risk and Reputation Committee.
|
Mr Donal Paul O'Dwyer | Non-Executive Director | Mar 2016 |
Mr O'Dwyer has knowledge of the health industry globally, after more than 35 years in senior executive and Non-Executive Director roles within the healthcare products and medical device sectors. Starting his career as a qualified civil engineer, he went on to gain experience in business, science, engineering, manufacturing and management. During his tenure with Baxter Healthcare, he rose through the ranks from plant manager to President of the Cardiovascular Group Europe, gaining understanding of the inner workings of business strategy and fiscal management, from the floor of the factory through to the boardroom. He then worked for Cordis (the cardiovascular device franchise of Johnson & Johnson) - initially as European President and later, when he located to the US, he served as Worldwide President. Donal has interest in environmental, social and governance factors and how these performance indicators can help promote long term financial success. Former directorships of listed entities in the past three year - Non-Executive Director of Fisher & Paykel Healthcare Corporation Ltd and Mesoblast Ltd. He is a member of the People Committee.
|
Mark Fitzgibbon | Chief Executive OfficerManaging Director | May 2007 |
Mr Fitzgibbon is a Director of nib health funds limited, as well as other nib holdings limited's subsidiaries. Mark has held executive positions at a number of Australian organisations, including local government councils and peak industry bodies. As Managing Director, Mark's focus has been to grow and diversify nib's business and with that, earnings by leveraging nib's capability, systems and people. This has seen nib grow in recent years organically and inorganically, in existing and new markets. Mark has previously served as CEO of the national and NSW peak industry bodies for licensed clubs, as well as holding several General Manager positions in local government.
|
Mr Peter Harmer | Non-Executive Director | Jul 2021 |
Mr Harmer has over 40 years of experience in the Australian and international insurance and financial sectors, including over 30 years in a senior executive capacity. He has understanding of the global insurance and reinsurance markets and has driven the improvement of business and customer experiences through digital innovation. During his career, Peter accelerated digital engagement through re-examining customer journeys to understand pain points and introduced the right tools and technology to help improve the overall customer experience. In addition, he has been focused on the development and design of working methodologies combined with Human Centred Design thinking to ensure practice in employee productivity, performance, health and wellbeing. Peter was formerly Chief Executive Officer of Insurance Australia Group (IAG), CGU Insurance, Aon Limited UK, Aon Risk Services Australia Pacific and Aon Re Australia and has led business' growth agendas, major acquisitions, and industry roll ups. Prior to his role as Chief Executive Officer at IAG, he took up a secondment role as Chief Digital Officer to help drive IAG's digital strategy. This included building a centralised capability to improve the customer experience through the utilisation of new technology and data insights. Peter is currently a Non-Executive Director of Commonwealth Bank of Australia, AUB Group Limited, and Tysers Insurance Broker Ltd, which is based in London, UK and is 100% owned by AUB Group Limited. Peter is the Chair of Lawcover Insurance Pty Ltd. He is also a member of the Advisory Council for Bain & Company, and Chair of the Asia/Pacific Advisory Council for EXL Services Limited. He is the Chair of the Risk and Reputation Committee and a member of the People Committee.
|
Ms Jacqueline Chow | Non-Executive Director | Apr 2018 |
Ms Chow has more than 20 years of experience working with global blue-chip consumer product multinationals in a range of executive and non-executive positions in general management, strategy, marketing as well as technology and innovation. Her early career concentrated on business analytics, brand equity and marketing. She has also led business transformation by driving productivity and efficiencies, as well as embedding leadership behaviours and change. Jacqueline contributes toward ensuring the sustainability of the organisations she serves in the areas of climate scenario impacts, human rights and supply chain resilience. Jacqueline has global experience driving strategic growth and innovation across customer and consumer brands for the likes of Fonterra, Campbell Arnott's and the Kellogg Company. She was previously Deputy Chair of Global Dairy Platform and a Director of Fisher & Paykel Appliances in New Zealand, Dairy Partners Americas, the Riddet Institute (Massey University NZ) and The Arnott's Foundation. Jacqueline is a senior advisor with McKinsey & Company's Transformation Practice where she advises clients across resources, retail, financial services, telecommunications and consumer sectors on organisational change and high performance culture. Jacqueline is currently a Non-Executive Director of Coles Group Limited and Charter Hall Group. Former directorships of listed entities in the past three years - Independent Non-Executive Director of Boral Limited. Jacqueline is a Non-Executive Director of the Australia-Israel Chamber of Commerce. She is Chair of the People Committee.
|
Mr Brad Welsh | Non-Executive Director | Jul 2023 |
Mr Welsh has spent more than a decade leading and advising global resource companies, including Energy Resources of Australia and Rio Tinto, bringing public sector and commercial skills to his role on nib's Board. Through his leadership roles in mining and energy, Brad has focused on operational efficiency, safety and building long-term relationships of trust with key stakeholders, including traditional landowners. Through media and senior advisory roles in the Office of the NSW Premier, the Minister for Planning, and the Prime Minister of Australia, he has acquired understanding of the public sector. Directorships of listed entities - Chief Executive Officer and Managing Director at Energy Resources of Australia Limited. Brad has been admitted as a solicitor to the NSW Supreme Court. He is a member of the Risk and Reputation Committee and People Committee.
|
Ms Jill Watts | Non-Executive Director | Jul 2023 |
Ms Watts has more than 40 years of experience leading global businesses. She has worked across the private sector, with governments affecting public policy change, and private research institutes. She has gained experience working with companies with operations in Australia, the UK, France, and South Africa. Prior to returning to Australia in 2017, Jill was the Group CEO of the UK's private hospital group, BMI Healthcare, responsible for 60 facilities across the UK. Jill was also Group CEO of Ramsay Healthcare, UK. In 2010, Jill was voted the most influential leader in UK Private Health Care. She has joined the Boards of a range of global companies since returning to Australia. Jill is currently a Non-Executive Director of IHH Healthcare Berhad, which is dual listed in Singapore and Malaysia. Jill is a prior Director of the Australian Chamber of Commerce, UK; The Royal Australian Flying Doctor Service, UK; Netcare Hospital Group, South Africa; Ramsay Generale de Sante, France; and Healthcare Logic Global Group. Jill is currently a Non-Executive Director at St Vincent's Healthcare and she is a Non-Executive Director at Icon Cancer Group. She is also a Board member at Keyton, a retirement villages business, formerly known as Lendlease Retirement Living. She is a member of the Risk and Reputation Committee.
|
Ms Roslyn Toms | Group Executive - Legal and Chief Risk OfficerCompany Secretary | Apr 2013 |
-
|
Mr Jordan French | Senior Corporate CounselJoint Company Secretary | Aug 2017 |
-
|
Martin Adlington | Chief Executive |
-
|
|
Rob Hennin | Chief Executive Officer nib New Zealand & nib Travel |
-
|
|
Edward Close | Chief Executive Australian Residents Health Insurance |
-
|
|
James Barr | Chief Executive International Visitors |
-
|
|
Nick Freeman | Group Chief Financial Officer |
-
|
|
Brendan Mills | Group Chief Information Officer |
-
|
|
Lauren Daniels | Group Chief People Officer |
-
|
|
Roslyn Toms | Group Executive - Legal and Chief Risk OfficerCompany Secretary |
-
|
|
Jordan French | Senior Corporate CounselJoint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited i | 84,292,191 | 17.38% |
Citicorp Nominees Pty Limited | 47,060,124 | 9.70% |
J P Morgan Nominees Australia Pty Limited | 46,183,080 | 9.52% |
National Nominees Limited | 13,023,146 | 2.68% |
BNP Paribas Noms Pty Ltd | 8,582,620 | 1.77% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 7,666,495 | 1.58% |
Bnp Paribas Nominees Pty Ltd <Agency Lending A/C> | 5,740,371 | 1.18% |
Bnp Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 3,682,626 | 0.76% |
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 2,969,775 | 0.61% |
Netwealth Investments Limited <Wrap Services A/C> | 1,235,303 | 0.25% |
Neweconomy Com Au Nominees Pty Limited <900 Account> | 1,137,763 | 0.23% |
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 1,096,101 | 0.23% |
Mr Mark Anthony Fitzgibbon | 1,084,491 | 0.22% |
Fitzy (Nsw) Pty Ltd <Fitz Family Fund A/C> | 946,621 | 0.20% |
Cpu Share Plans Pty Ltd <Nhf Escrow Trust Master A/C> | 850,693 | 0.18% |
HSBC Custody Nominees (Australia) Limited ii | 842,297 | 0.17% |
Bnp Paribas Noms (Nz) Ltd | 828,923 | 0.17% |
Netwealth Investments Limited <Super Services A/C> | 826,644 | 0.17% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 788,600 | 0.16% |
Ioof Investment Services Limited <Ips Superfund A/C> | 643,141 | 0.13% |